Sickle Cell Disease (SCD)

Rare Disease·MeSH: Anemia, Sickle Cell

Prevalence

101.5 / 100K

Incidence

7.0 / 100K/yr

12 drugs in development·6 companies·2 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
CASGEVY	CRISPR Therapeutics AG (CRSP)
CASGEVY (exagamglogene autotemcel)	Editas Medicine, Inc. (EDIT)
oxbryta	Global Blood Therapeutics, Inc. (GBT)
PYRUKYND®	AGIOS PHARMACEUTICALS, INC. (AGIO)

Phase 3(2)

Drug	Company
crizanlizumab	Novartis AG (NVS)
inclacumab	Global Blood Therapeutics, Inc. (GBT)

Phase 1(3)

Drug	Company
gbt601	Global Blood Therapeutics, Inc. (GBT)
reni-cel	Editas Medicine, Inc. (EDIT)
renizgamglogene autogedtemcel (reni-cel)	Editas Medicine, Inc. (EDIT)

Preclinical(1)

Drug	Company
In vivo HSC gene editing program for SCD and TDT	Editas Medicine, Inc. (EDIT)

Phase 2/Phase 3(1)

Drug	Company
ft-4202	Forma Therapeutics Holdings, Inc. (FMTX)

Phase 4(1)

Drug	Company
Crizanlizumab	Novartis AG (NVS)

BioSniper tracks 12 drugs in development for Sickle Cell Disease (SCD) across 6 companies.

There are 2 clinical trials targeting Sickle Cell Disease (SCD) tracked by BioSniper.

The estimated prevalence of Sickle Cell Disease (SCD) is approximately 101.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.